Development of an HIV Rev-dependent dual-reporter cell for anti-HIV drug screenin

开发用于抗 HIV 药物筛选的 HIV Rev 依赖性双报告细胞

基本信息

批准号：
8138239
负责人：
YUNTAO WU
金额：
$ 7.1万
依托单位：
GEORGE MASON UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2011
资助国家：
美国
起止时间：
2011-07-05 至 2013-06-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8138239
关键词：
AIDS/HIV problem Acquired Immunodeficiency Syndrome Anti-HIV Agents Anti-Retroviral Agents Antibodies Biological Assay CCR5 gene Cell Line Cells Chemicals Dependency Development Exhibits Flow Cytometry Gene Expression Grant HIV HIV Antibodies HIV Infections HIV Long Terminal Repeat Hela Cells Highly Active Antiretroviral Therapy Immune In Vitro Inhibitory Concentration 50 Lactamase Lentivirus Vector Libraries Long Terminal Repeats Luciferases Measures Mediating Methodology Mitogens Multi-Drug Resistance Mutation Noise Pharmaceutical Preparations Preclinical Drug Evaluation Probability Reagent Reporter Reporter Genes Reporting Research Research Methodology Response Elements Screening procedure Signal Transduction Suspension substance Suspensions System Technology Testing Transcriptional Activation Translations United States National Institutes of Health Up-Regulation Ursidae Family Viral Viral Load result Virus base cytokine cytotoxicity drug candidate drug discovery high throughput screening inhibitor/antagonist novel novel therapeutics nucleocytoplasmic transport pandemic disease programs promoter prospective repository tat Protein transcription factor treatment planning

项目摘要

DESCRIPTION (provided by applicant): HIV/AIDS is a worldwide pandemic afflicting 40 million people, and currently there is no cure. The proposed research is to develop a new reporter cell line to facilitate the discovery of novel anti-HIV drugs. This prospective reporter cell system will employ a Rev-dependent lentiviral vector, which has been shown previously to be highly specific to HIV infection. This novel system will greatly facilitate the development of a novel cell- based drug screening platform. Additionally, by employing two reporters this system can be used in multiple assay formats and would be amenable to high-throughput screens for antiretroviral compounds. PUBLIC HEALTH RELEVANCE: This NIH R03 Small Research Program grant is to develop a new research methodology, namely, the development of a new Rev-dependent cell line to screen for anti-HIV drugs. HIV infection causes AIDS that afflicted approximately 40 million people globally. This proposed research will facilitate the development of new therapeutics.

描述（由申请人提供）：艾滋病毒/艾滋病是一种全球性流行病，困扰着 4000 万人，目前尚无治愈方法。拟议的研究是开发一种新的报告细胞系，以促进新型抗艾滋病毒药物的发现。该前瞻性报告细胞系统将采用 Rev 依赖性慢病毒载体，该载体先前已被证明对 HIV 感染具有高度特异性。这种新颖的系统将极大地促进新型细胞药物筛选平台的开发。此外，通过采用两个报告基因，该系统可以用于多种测定形式，并且适合抗逆转录病毒化合物的高通量筛选。公共健康相关性：NIH R03 小型研究计划拨款旨在开发一种新的研究方法，即开发一种新的 Rev 依赖性细胞系来筛选抗 HIV 药物。 HIV 感染导致艾滋病，全球约有 4000 万人受其困扰。这项拟议的研究将促进新疗法的开发。